ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial (ASSAIL-MI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03004703|
Recruitment Status : Active, not recruiting
First Posted : December 29, 2016
Last Update Posted : March 4, 2020
|Condition or disease||Intervention/treatment||Phase|
|Coronary Disease Myocardial Infarction||Drug: Tocilizumab Drug: Sodium chloride 0.9%||Phase 2|
Myocardial infarction (MI) is a major contributor to morbidity and mortality in the Western world. The main determinant of death and complications is infarct size, and limitation of the infarct size has therefore been an important objective for strategies to improve outcome. In patients presenting with an acute ST segment elevation myocardial infarction (STEMI), urgent myocardial reperfusion with percutaneous coronary intervention (PCI) is the most effective treatment to this end. However, despite PCI, the morbidity and mortality in patients with STEMI remain substantial. This fact suggests that other, adjuvant strategies are required to reduce infarct size and improve outcome. The inflammatory cytokine interleukin (IL)-6 is an important mediator of plaque destabilisation and rupture in acute coronary syndrome (ACS) and may contribute to the ischemia-reperfusion injury succeeding revascularisation. Experimental studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory mechanisms.(ref)
The investigators recently conducted a double blind, placebo controlled trial in 117 patients with non-ST segment elevation myocardial infarction (NSTEMI) who presented within 72 hour after the onset of chest pain. In this study, a single, intravenous dose of the IL-6 antagonist tocilizumab reduced the inflammatory activity by more than 50% in the days subsequent to the intervention. Importantly, tocilizumab also reduced troponin T (TnT) levels, suggesting that patients receiving tocilizumab sustained less myocardial damage than patients who received placebo.1
Interleukin-6 inhibition might limit infarct size through reduced myocardial inflammation, but theoretically, it could also inhibit the repair process within the injured area. While the recent study suggests that IL-6 inhibition has largely favourable effects in NSTEMI, it remains to be seen if similar, beneficial effects can be obtained in patients with STEMI. On this background, the investigators want to investigate the effect of tocilizumab in patients with acute STEMI. The postulate is that a single dose of tocilizumab (RoActemra®) will have favourable effects on infarct size, as assessed by markers of myocardial necrosis and cardiac magnetic resonance imaging (CMR), without negative consequences for the repair process in these patients. The hypothesis will be tested in a randomised, double blind, placebo controlled trial comprising 200 patients with acute STEMI.
This is a phase 2 study on a new and exciting anti-inflammatory strategy in cardiovascular disease. It will be conducted at three experienced, high volume centres in Norway, and will target new and yet unmodified mechanisms during myocardial infarction. The ambition is to improve the prognosis of patients with ACS, with potential to change clinical practice.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial|
|Actual Study Start Date :||March 16, 2017|
|Actual Primary Completion Date :||February 19, 2020|
|Estimated Study Completion Date :||July 30, 2020|
Experimental: Active drug
Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
Other Name: RoActemra®,
Placebo Comparator: Placebo
Sodium chloride 0.9%; 100 ml i.v. once.
Drug: Sodium chloride 0.9%
Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
Other Name: NaCl 0.9%
- The primary endpoint will be the between-group difference in the myocardial salvage index as measured in the acute phase by cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE). [ Time Frame: 6 months ]
- The between-group difference in the AUC for Troponin T (TnT) during index hospitalisation [ Time Frame: 24 -72 hours after randomisation ]
- The extent of microvascular obstruction as measured by CMR after 3 - 7 days [ Time Frame: 3 - 7 days after randomisation ]
- Final infarct size as measured by CMR 6 months after randomisation [ Time Frame: 6 months after randomisation ]
- Left ventricular size as assessed by CMR 6 months after randomisation [ Time Frame: 6 months after randomisation ]
- Baseline-adjusted NT-proBNP at 6 months after randomisation [ Time Frame: 6 months after randomisation ]
- The AUC of Creatine Kinase-MB (CK-MB) during index hospitalisation [ Time Frame: 24-72 hours after randomisation ]
- The AUC of C-reactive protein (CRP) during index hospitalisation [ Time Frame: 24-72 hours after randomisation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004703
|Oslo University Hospital, Rikshospitalet|
|Oslo, Norway, 0424|
|Oslo University Hospital, Ullevål|
|Oslo, Norway, 0424|
|St. Olav Hospital|
|Trondheim, Norway, 7006|
|Principal Investigator:||Lars Gullestad, Professor, MD, PhD||Oslo University Hospital|
|Study Chair:||Bjørn Bendz, Associate Professor, MD, PhD||Oslo University Hospital|
|Study Chair:||Pål Aukrust, Professor, MD, PhD||Oslo University Hospital|
|Study Chair:||Svend Aakhus, Professor, MD, PhD||Oslo University Hospital|
|Study Chair:||Rune Wiseth, Professor, MD, PhD||St. Olavs Hospital|
|Study Chair:||Jan Kristian Damaas, Professor, MD, PhD||St. Olavs Hospital|
|Study Chair:||Geir Øystein Andersen, MD, PhD||Oslo University Hospital, Ullevål|
|Study Chair:||Nils Einar Kløw, Professor, MD, PhD||Oslo University Hospital, Ullevål|
|Study Chair:||Anders Opdahl, MD, PhD||Oslo University Hospital, Ullevål|